Lanean...
New emerging targets in cancer immunotherapy: the role of VISTA
The immune surveillance system is complex and regulated by different actors. Programmed death protein-ligand 1 (PD-L1), the only approved biomarker in clinical practice, has proven to be imperfect in selecting patients to immune checkpoint inhibitors treatment. Therefore, new biomarkers, and new the...
Gorde:
| Argitaratua izan da: | ESMO Open |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BMJ Publishing Group
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7305420/ https://ncbi.nlm.nih.gov/pubmed/32554470 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2020-000683 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|